HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
Open Access
- 3 January 2020
- journal article
- letter
- Published by Wiley in HemaSphere
- Vol. 4 (1), e325
- https://doi.org/10.1097/hs9.0000000000000325
Abstract
Supplemental Digital Content is available in the text.Funding Information
- KWF Kankerbestrijding
- Celgene
- Roche
- Celgene
- Roche
This publication has 15 references indexed in Scilit:
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialThe Lancet Oncology, 2014
- Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphomaBritish Journal of Haematology, 2014
- Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapyBlood, 2009
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivoAmerican Journal of Hematology, 2009
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor CellsClinical Cancer Research, 2008
- Lenalidomide for the Treatment of B-Cell MalignanciesJournal of Clinical Oncology, 2008
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating AgentsClinical Cancer Research, 2008
- Lymphoma microenvironment: culprit or innocent?Leukemia, 2007
- Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic FactorsJournal of Clinical Oncology, 2005